FDA approves #giredestrant + everolimus for ER+/HER2- MBC.
As I expected, the FDA approved it only for ESR1-mutant tumors (#evERA: PFS 10.0 vs 5.5 mo, HR 0.38).
For non-mutated tumors after CDK4/6i, options remain extremely limited, making the #gedatolisib approval (VIKTORIA-1) in that population critical.
As I expected, the FDA approved it only for ESR1-mutant tumors (#evERA: PFS 10.0 vs 5.5 mo, HR 0.38).
For non-mutated tumors after CDK4/6i, options remain extremely limited, making the #gedatolisib approval (VIKTORIA-1) in that population critical.